Ascendis Pharma (NASDAQ:ASND) Full Year 2024 Results

Key Financial Results

• Revenue: €363.6m (up 36% from FY 2023).
• Net loss: €378.1m (loss narrowed by 22% from FY 2023).
• €6.53 loss per share (improved from €8.55 loss in FY 2023).

ASND Products In Clinical Trials

• Phase II: 6.

ASND Post-Clinical Trial Products

• Pre-registration: 3.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ascendis Pharma Revenues and Earnings Beat Expectations

Revenue exceeded analyst estimates by 13%. Earnings per share (EPS) also surpassed analyst estimates by 4.4%.

The primary driver behind last 12 months revenue was the North America segment contributing a total revenue of €233.2m (64% of total revenue). The largest operating expense was Research & Development (R&D) costs, amounting to €307.0m (44% of total expenses). Explore how ASND's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US.

The company's shares are up 14% from a week ago.

Risk Analysis

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.